Attached files
| file | filename |
|---|---|
| EX-99.1 - EX-99.1 - Cidara Therapeutics, Inc. | cdtx-ex991_2015052153.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 21, 2015
Cidara Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
|
|
Delaware |
|
2836 |
|
46-1537286 |
|
(State or Other Jurisdiction of Incorporation or Organization) |
|
(Primary Standard Industrial Classification Code Number) |
|
(I.R.S. Employer Identification Number) |
6310 Nancy Ridge Drive, Suite 101
San Diego, California 92121
(858) 752-6170
(Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrant’s Principal Executive Offices)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:
|
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
In this report, “Cidara Therapeutics,” “Cidara,” “Company,” “we,” “us” and “our” refer to Cidara Therapeutics, Inc.
Item 2.02 Results of Operations and Financial Condition.
On May 21, 2015, we issued a press release reporting our financial results for the first quarter ended March 31, 2015. The full text of the press release is furnished as exhibit 99.1 to this Current Report on Form 8-K.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
|
|
|
|
|
Exhibit No. |
|
Description |
|
|
|
|
|
99.1 |
|
Press release issued May 21, 2015, reporting financial results for the first quarter ended March 31, 2015. |
|
|
|
|
2
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
Cidara Therapeutics, Inc. |
||
|
|
|
|
||
|
Dated: May 21, 2015 |
|
By: |
|
/s/ Jeffrey L. Stein |
|
|
|
|
|
Jeffrey L. Stein |
|
|
|
|
|
President and Chief Executive Officer (Principal Executive Officer) |
3
|
|
|
|
|
Exhibit No. |
|
Description |
|
|
|
|
|
99.1 |
|
Press release issued May 21, 2015, reporting financial results for the first quarter ended March 31, 2015. |
|
|
|
|
4